Private health insurance premiums will be going up in 2026 — in some cases, by a lot. Congressional Democrats and Republicans ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight management has undergone a seismic shift. Zealthy is one of the fastest-growing telehealth weight-loss platforms in the ...

FDA-approved weight loss medications include injections (Wegovy®, Zepbound®, etc.) and pills, like Qsymia® and Xenical®. Most ...

Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved ...

When was the last time a prescription drug changed how entire nations eat, shop, travel, dress and spend? According to a ...

Move over Ozempic, Wegovy, Mounjaro and Zepbound - Eli Lilly says another contender may be on the way. The pharmaceutical giant announced encouraging results from a Phase 3 clinical trial of its ...

With the market heading into 2026, investors are looking for companies that can keep delivering strong revenue and expanding ...

In a significant move to address supply constraints, Eli Lilly announced a $6 billion investment to construct a new manufacturing facility in Huntsville, Alabama. This site is slated to produce both ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...